Opinion
Video
Key Takeaways for Concurrent Biomarker Testing in NSCLC
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, emphasize the critical role of both tissue and liquid biopsies, the necessity of rapid time-to-treatment initiation, and the increasing likelihood of liquid biopsies becoming the standard of care for metastatic non-small cell lung cancer patients in the near future.
EP: 1.Optimizing NSCLC Patient Outcomes Through Concurrent Biomarker Testing
EP: 2.Concurrent NSCLC Biomarker Testing at Diagnosis
EP: 3.NCCN Guidelines: Optimizing NSCLC Treatment with Concurrent Biomarker Testing
EP: 4.Improving Time-to-Treatment for Patients With Non-Small Cell Lung Cancer
EP: 5.Biomarker Testing in Early-Stage NSCLC
EP: 6.Reflex Testing for Patients with Suspected Lung Cancer
EP: 7.Challenges of NSCLC Biomarker Testing in Clinical Practice
EP: 8.Overcoming Barriers to NSCLC Biomarker Testing
Now Viewing
EP: 9.Key Takeaways for Concurrent Biomarker Testing in NSCLC
Related Videos
Related Content
%20(2)%201-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered.jpg?fit=crop&auto=format)
